Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study

Table 3 Illness perception (assessed by BIPQ) following omalizumab treatment at each time point (longitudinal population)

Component	Baseline	Change at 6 months from baseline	P-value	Change at 12 months from baseline	P-value
Consequences	7.3 ± 1.9	−2.0 ± 2.4	< 0.0001	−2.2 ± 2.7	< 0.0001
Timeline	8.1 ± 2.4	−1.0 ± 2.5	< 0.0001	−0.3 ± 2.4	0.1938
Personal control	5.9 ± 2.0	0.7 ± 2.3	0.0005	0.9 ± 2.5	0.0003
Treatment control	7.2 ± 2.3	0.9 ± 2.6	0.0001	1.1 ± 2.5	< 0.0001
Identity	7.6 ± 1.7	−2.2 ± 2.5	< 0.0001	−2.0 ± 2.6	< 0.0001
Concern	7.4 ± 2.3	−1.6 ± 3.0	< 0.0001	− 1.7 ± 3.0	< 0.0001
Emotions	7.0 ± 2.6	−1.2 ± 2.8	< 0.0001	−1.1 ± 3.0	< 0.0001
Illness comprehensibility	7.1 ± 2.3	0.4 ± 2.3	0.0690	0.7 ± 2.4	0.0076

Data presented as mean ± SD
P < 0.05 is considered as statistically significant. P-value was calculated using Wilcoxon test
BIPQ Brief Illness Perception Questionnaire

ISSN: 1939-4551